Phase 3 Clinical Trials With Primary Completion Dates in February 2020

This is a list of Phase 3 trials with primary completion dates in February 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
BYSI BeyondSpring Inc. 2020-02-01 Phase 3 NCT02504489 Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
CHHL China Holdings, Inc. 2020-02-01 Phase 3 NCT02856126 HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
DBVT DBV Technologies S.A. 2020-02-01 Phase 3 NCT03013517 Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children
IPSEY Ipsen S.A. 2020-02-01 Phase 3 NCT02683941 Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors
MCRB Seres Therapeutics, Inc. 2020-02-01 Phase 3 NCT03183141 ECOSPOR IV: An Open-Label Extension of Study SERES 012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection
MDLH Medical International Technology, Inc. 2020-02-01 Phase 3 NCT04029545 A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation
MNLO Menlo Therapeutics Inc. 2020-02-01 Phase 3 NCT03546816 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
MYGN Myriad Genetics, Inc. 2020-02-01 Phase 3 NCT02655016 A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
OCUL Ocular Therapeutix, Inc. 2020-02-01 Phase 3 NCT04061044 A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert
OCUL Ocular Therapeutix, Inc. 2020-02-01 Phase 3 NCT04050865 A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
OMER Omeros Corporation 2020-02-01 Phase 3 NCT03205995 Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
OSMT Osmotica Pharmaceuticals plc 2020-02-01 Phase 3 NCT03319732 A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
ZGNX Zogenix, Inc. 2020-02-01 Phase 3 NCT03790137 Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).